RYBREVANT ® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations National... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 1, 2024 Category: Pharmaceuticals Tags: FDA TRI Source Type: news
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
On March 1, 2024, the FDAapproved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Upstate ’s robotic lung cancer surgery success rate hits new milestone
All lobectomies for stage one lung cancer are being performed with minimally invasive surgery. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - March 1, 2024 Category: Universities & Medical Training Tags: News Source Type: news
Rybrevant (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, New Jersey (March 01, 2024)– Johnson& Johnson (NYSE: JNJ) announced today that following a priority review, the U.S. Food and Drug Administration (FDA) has approved Rybrevant® (amivantamab-vmjw) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 1, 2024 Category: Drugs & Pharmacology Source Type: news
Radiologists and AI-powered health informatics: Leading the way in screening
Sham Sokka, chief operating and technology officer of DeepHealth, discusses why he is excited about this year’s ECR congress in Vienna.
What are you most excited about for ECR this year?
Vienna is such a beautiful city and I’m so excited to be here at The European Congress of Radiology (ECR 2024) again this year.
At DeepHealth, this represents an exciting time – to showcase our pioneering offering, present new data, and meet and network with experts in the field of screening and radiology. I always relish the opportunity to talk to our customers from around the world.
Everything we do at DeepHealth is about empow...
Source: AuntMinnie.com Headlines - February 29, 2024 Category: Radiology Authors: DeepHealth Tags: Artificial Intelligence Source Type: news
AI can aid radiologists in the fight against lung cancer
AI software can come to the aid of overwhelmed radiologists by aiding in the crucial tasks of detection, quantification, and future risk prediction of lung cancer on CT exams -- both in low-dose screening exams and in nonscreening chest CT exams.
Radiologists inundated with lung nodule findings may find that AI can come to their aid in the crucial tasks of detection, quantification, and future risk prediction of lung cancer on CT exams -- both in low-dose screening exams and in nonscreening chest CT exams.
Among common incidental findings in medical imaging, pulmonary nodules appear on about one-third of chest CT scans l...
Source: AuntMinnie.com Headlines - February 29, 2024 Category: Radiology Authors: Liz Carey Tags: Clinical News Artificial Intelligence Source Type: news
Lunit to present studies at ECR 2024
Lunit will highlight four oral presentations and three poster presentations at ECR 2024, ranging from adaptability in different use cases to the potential to act as an independent reader in mammography double-reading settings.
Oral presentations featuring Lunit INSIGHT at ECR 2024 include the following:
ul.editorialList li {margin-bottom:6px;}
“The performance of a commercial artificial intelligence algorithm in an external quality assurance scheme regularly used by humans in the NHS breast screening programme” (ACV 2024 Research Stage 2, February 28, 3 p.m. to 4 p.m.)
“The Multi- Sixteen Thousand and Counting:...
Source: AuntMinnie.com Headlines - February 28, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
4 Sneaky Signs Of Lung Cancer You Should Know
Get your regular screenings, and don't ignore or dismiss these subtle symptoms. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - February 27, 2024 Category: Consumer Health News Source Type: news
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), (Source: World Pharma News)
Source: World Pharma News - February 27, 2024 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Her mom's lung cancer was caught too late. It's part of a pattern in Nunavik
A study published in the Canadian Medical Association Journal found that Nunavik patients had a shorter survival rate after lung cancer diagnosis compared to Montreal residents. (Source: CBC | Health)
Source: CBC | Health - February 27, 2024 Category: Consumer Health News Tags: News/Canada/Montreal Source Type: news
Innovative chemotherapy approach shows promise against lung cancer
Lung cancer is not the most common form of cancer, but it is by far the deadliest.
Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer kills more than 1.8 million people worldwide each year, according to the World Health Organization. (Source: World Pharma News)
Source: World Pharma News - February 26, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Renowned Thoracic Surgeon Enhances Mesothelioma Care in FL
Dr. Rodney Landreneau is joining the renowned Thoracic Surgical Program at Tampa General Hospital. He spent decades caring for patients with pleural mesothelioma and lung cancer patients in Western Pennsylvania at the University of Pittsburgh and Penn Highlands Healthcare. He’s now moved more than 1,000 miles to help augment Tampa General Hospital Cancer Institute’s successful patient care.
Landreneau has nearly 40 years of experience treating malignant pleural mesothelioma and lung cancer, as well as benign and malignant diseases of the esophagus. An internationally recognized scientific investigator in the treatme...
Source: Asbestos and Mesothelioma News - February 26, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Cancer Center Doctors/Specialists Mesothelioma Treatment Source Type: news
Lung Cancer Survival Worse Among Canadian Inuit in Quebec Lung Cancer Survival Worse Among Canadian Inuit in Quebec
A new study showed shorter survival among Inuit patients with lung cancer who were treated at McGill University, suggesting disparities in health services.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 26, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
European Approval for Lung and Skin Cancer Drugs European Approval for Lung and Skin Cancer Drugs
The European Medicines Agency granted marketing authorization for tislelizumab and retifanlimab for the treatment of non –small cell lung cancer and Merkel cell carcinoma, respectively.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 23, 2024 Category: Dermatology Tags: Hematology-Oncology Source Type: news
Changing the Surgical Paradigm in Oligometastatic NSCLC
(MedPage Today) -- Patients with single-site synchronous oligometastatic non-small cell lung cancer (NSCLC) had better overall survival (OS) when they received surgery for their primary tumor, a retrospective review of nationwide data showed.... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 23, 2024 Category: Hematology Source Type: news
